Session Information
Date: Thursday, June 23, 2016
Session Title: Clinical trials and therapy in movement disorders
Session Time: 12:00pm-1:30pm
Location: Exhibit Hall located in Hall B, Level 2
Objective: To conduct a systematic review to evaluate the efficacy, safety, and dosing range of quetiapine for the treatment for hallucinosis / psychosis in patients with PD.
Background: Although quetiapine is considered a first-line pharmacological agent for the treatment hallucinosis / psychosis in PD, a systematic literature review of quetiapine for this condition has not been previously published.
Methods: A systematic literature search (PubMed, Cochrane Library, and EMBASE) was performed from to identify randomized controlled trials and other comparative clinical studies of quetiapine for treatment of hallucinosis / psychosis in PD (published between January 1991 and December 2015). Study methodology, patient- and treatment-level data were independently extracted and then summarized using descriptive statistics. Randomized and nonrandomized studies underwent quality assessment for risk of bias based on Cochrane and TREND metrics, respectively. Documentation of the inclusion and exclusion process is presented in the Preferred Reporting Items of Systematic Reviews and Meta-Analyses (PRISMA) format.
Results: 1,126 potentially relevant articles were identified and 7 randomized clinical studies met the inclusion/exclusion and data extraction criteria. Quetiapine doses ranged between 12.5 mg and 300 mg per day. In 4 of 5 placebo-controlled studies, quetiapine failed to significantly improve psychosis; study authors cited high dropout rates and small sample size as limitations for conclusive interpretation of results. In 2 clozapine-comparator controlled studies, quetiapine demonstrated non-inferiority with improvements in Brief Psychiatric Rating Score or Clinical Global Impression of Change. Overall, reported adverse events included dizziness, somnolence, orthostatic hypotension, and sedation.
Conclusions: Quetiapine has demonstrated non-inferiority to clozapine for management of hallucinosis / psychosis in patients with PD but has not demonstrated efficacy compared to placebo.
To cite this abstract in AMA style:
K. Dashtipour, J.J. Chen, L. Massihi, S. Tashiro, K. Frei. Systematic literature review of quetiapine for hallucinosis / psychosis in Parkinson’s disease (PD) [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/systematic-literature-review-of-quetiapine-for-hallucinosis-psychosis-in-parkinsons-disease-pd/. Accessed June 14, 2025.« Back to 2016 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/systematic-literature-review-of-quetiapine-for-hallucinosis-psychosis-in-parkinsons-disease-pd/